As of 24 March 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,106,191 shares (each share ...

No. 5 / 2025Zealand Pharma increases its share capital as a result of the exercise of employee warrantsCopenhagen, ...

Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...

Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide ...

COPENHAGEN - Zealand Pharma A/S (NASDAQ:ZEAL), a Danish biotechnology firm with a market capitalization of $5.8 billion, has announced a nominal increase to its share capital following the ...

Copenhagen, Denmark, March 20, 2025 - Zealand Pharma A/S ("Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based ...

COPENHAGEN - Zealand Pharma A/S (NASDAQ:ZEAL), a Danish biotechnology firm with a market capitalization of $5.8 billion, has announced a nominal increase to its share capital following the exercise of ...

For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with ...

The biotech industry may be cooling off, but there’s still plenty to be excited about when it comes to the underlying ...